Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma

Fable Zustovich; Giuseppe Lombardi; Davide Pastorelli; Patrizia Farina; Massimo dal Bianco; Luca de Zorzi; Maurizia Dalla Palma; Ornella Nicoletto; Vittorina Zagonel

doi:10.2147/OAJU.S7230

Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma

Fable Zustovich, Giuseppe Lombardi, Davide Pastorelli, Patrizia Farina, Massimo dal Bianco, Luca de Zorzi, Maurizia Dalla Palma, Ornella Nicoletto, Vittorina Zagonel

Istituto Oncologico Veneto

Research output: Contribution to journal › Article › peer-review

Abstract

Renal cell carcinoma (RCC) is a common malignancy worldwide with approximately 95,000 new cases per year and ranks as the sixth cause of cancer deaths. Until recently, the slightly active and very toxic cytokines were available for patients with advanced RCC. Advances have been made in understanding the molecular biology of renal cancer. The introduction of targeted agents has led to promising possibilities for treating these highly vascularized tumors. Angiogenesis inhibition is likely to represent the main potential therapeutic target. Sorafenib is an oral multikinase inhibitor with activity against tyrosine kinase receptors that are responsible for blood vessel development and has shown to be active in treating advanced RCC. In this review, we summarize the pharmacology, mode of action, pharmacokinetics, and safety of sorafenib use in therapy for advanced RCC.

Original language	English
Pages (from-to)	69-82
Number of pages	14
Journal	Open Access Journal of Urology
Volume	3
Issue number	1
DOIs	https://doi.org/10.2147/OAJU.S7230
Publication status	Published - 2011

Keywords

Angiogenesis
Pharmacokinetics
Sorafenib

ASJC Scopus subject areas

Urology

Access to Document

10.2147/OAJU.S7230

Cite this

@article{3ab05fd9f41440978822df2733773867,

title = "Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma",

abstract = "Renal cell carcinoma (RCC) is a common malignancy worldwide with approximately 95,000 new cases per year and ranks as the sixth cause of cancer deaths. Until recently, the slightly active and very toxic cytokines were available for patients with advanced RCC. Advances have been made in understanding the molecular biology of renal cancer. The introduction of targeted agents has led to promising possibilities for treating these highly vascularized tumors. Angiogenesis inhibition is likely to represent the main potential therapeutic target. Sorafenib is an oral multikinase inhibitor with activity against tyrosine kinase receptors that are responsible for blood vessel development and has shown to be active in treating advanced RCC. In this review, we summarize the pharmacology, mode of action, pharmacokinetics, and safety of sorafenib use in therapy for advanced RCC.",

keywords = "Angiogenesis, Pharmacokinetics, Sorafenib",

author = "Fable Zustovich and Giuseppe Lombardi and Davide Pastorelli and Patrizia Farina and {dal Bianco}, Massimo and {de Zorzi}, Luca and Palma, {Maurizia Dalla} and Ornella Nicoletto and Vittorina Zagonel",

year = "2011",

doi = "10.2147/OAJU.S7230",

language = "English",

volume = "3",

pages = "69--82",

journal = "Open Access Journal of Urology",

issn = "1179-1551",

publisher = "Dove Medical Press Ltd.",

number = "1",

}

TY - JOUR

T1 - Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma

AU - Zustovich, Fable

AU - Lombardi, Giuseppe

AU - Pastorelli, Davide

AU - Farina, Patrizia

AU - dal Bianco, Massimo

AU - de Zorzi, Luca

AU - Palma, Maurizia Dalla

AU - Nicoletto, Ornella

AU - Zagonel, Vittorina

PY - 2011

Y1 - 2011

N2 - Renal cell carcinoma (RCC) is a common malignancy worldwide with approximately 95,000 new cases per year and ranks as the sixth cause of cancer deaths. Until recently, the slightly active and very toxic cytokines were available for patients with advanced RCC. Advances have been made in understanding the molecular biology of renal cancer. The introduction of targeted agents has led to promising possibilities for treating these highly vascularized tumors. Angiogenesis inhibition is likely to represent the main potential therapeutic target. Sorafenib is an oral multikinase inhibitor with activity against tyrosine kinase receptors that are responsible for blood vessel development and has shown to be active in treating advanced RCC. In this review, we summarize the pharmacology, mode of action, pharmacokinetics, and safety of sorafenib use in therapy for advanced RCC.

AB - Renal cell carcinoma (RCC) is a common malignancy worldwide with approximately 95,000 new cases per year and ranks as the sixth cause of cancer deaths. Until recently, the slightly active and very toxic cytokines were available for patients with advanced RCC. Advances have been made in understanding the molecular biology of renal cancer. The introduction of targeted agents has led to promising possibilities for treating these highly vascularized tumors. Angiogenesis inhibition is likely to represent the main potential therapeutic target. Sorafenib is an oral multikinase inhibitor with activity against tyrosine kinase receptors that are responsible for blood vessel development and has shown to be active in treating advanced RCC. In this review, we summarize the pharmacology, mode of action, pharmacokinetics, and safety of sorafenib use in therapy for advanced RCC.

KW - Angiogenesis

KW - Pharmacokinetics

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=79957807483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957807483&partnerID=8YFLogxK

U2 - 10.2147/OAJU.S7230

DO - 10.2147/OAJU.S7230

M3 - Article

AN - SCOPUS:79957807483

SN - 1179-1551

VL - 3

SP - 69

EP - 82

JO - Open Access Journal of Urology

JF - Open Access Journal of Urology

IS - 1

ER -

Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this